Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tabalumab - Eli Lilly and Company

Drug Profile

Tabalumab - Eli Lilly and Company

Alternative Names: Anti-BAFF MAb; Anti-BAFF monoclonal antibody; LY 2127399

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Multiple sclerosis; Renal failure; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 17 May 2018 Eli Lilly terminates the phase IIIb Illuminate-X trial for Systemic lupus erythematosus in USA, Austria, Hungary, Spain, Latvia, Bulgaria, Italy, the United Kingdom, Germany, and Croatia (NCT01488708)
  • 01 Nov 2015 Eli Lilly terminates phase III trial in Systemic lupus erythematosus in USA, South Korea, Mexico and Puerto Rico due to lack of efficacy (NCT02041091)
  • 01 Aug 2015 Eli Lilly completes a phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Japan (IV) (NCT01556438)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top